Israel-based MigVax Corp, a company developing its MigVax-101 vaccine for COVID-19, announced on Tuesday that it has named Dr Eyal Desheh as the chairman of its board of directors.
Dr Desheh has been serving as chairman of the board of directors of Isracard Group. He has also been the executive vice president and chief financial officer of Teva Pharmaceuticals and executive vice president and chief financial officer of Check Point Software Technologies.
Dr Desheh said said, 'I am very happy to join this global effort to defeat the COVID-19 pandemic which has devastated our world by creating a severe health and economic crisis. An amazing and talented team of scientists in the north of Israel created a promising infrastructure for the development of vaccines for COVID-19 and its' like. At MigVax we are working as hard and as fast as we can to make this a reality.'
Moderna and Catalent Team for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate
Akeso names new lead gynecologic oncology advisor and chair of the Steering Committee
Therapeutics Solutions International plans to use StemVacs for COVID-19 patient treatment
Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate
Epsilen Bio Names Berretta as Chief Executive Officer and Simon as Chairman of the Board
CANbridge Pharmaceuticals appoints Carrie Ann Cook new SVP/global head of Business Development